腹主动脉瘤患者血浆miRNA-181b与miRNA-21的表达及其对腔内治疗后临床结局的影响
研究纳入47例有EVAR指征的腹主动脉瘤患者和10例无合并症对照,检测术前及随访6个月时miRNA-181b与miRNA-21血清水平。患者全血中两种miRNA过表达,EVAR后表达下降;miRNA表达与内漏、瘤径或所用装置类型均不相关。
要点
- 腹主动脉瘤患者全血中miRNA-181b与miRNA-21呈过表达。
- EVAR术后6个月两种miRNA表达较术前下降。
- miRNA表达与内漏、瘤径及EVAR装置类型均不相关。
核心结论
- miRNA-181b与miRNA-21在腹主动脉瘤患者中过表达且EVAR后降低,可能提示其可作为随访的潜在生物标志物,但miRNA未能识别内漏或区分其亚型。
研究设计与样本
- 研究纳入47例有EVAR指征的腹主动脉瘤患者和10例无合并症对照,检测术前及随访6个月时miRNA-181b与miRNA-21血清水平,对照组仅检测一次。
主要发现
- 腹主动脉瘤患者全血中观察到miRNA-181b与miRNA-21过表达。
- 腹主动脉瘤患者EVAR后所研究miRNA表达下降,提示排除瘤囊改变这些标志物表达。
- miRNA表达与内漏、动脉瘤直径或EVAR所用不同装置类型均不相关。
临床怎么用
- 作者认为miRNA-181b与miRNA-21过表达及其EVAR后降低可能提示这些分子可作为此类患者随访的潜在生物标志物。
- 作者指出miRNA未能识别可能的内漏或将其区分为亚型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Abdominal aortic aneurysms (AAA) are major causes of morbidity and mortality in the elderly population. Endovascular aneurysm repair (EVAR) is associated with lower complications rates than conventional treatment; however, rigorous follow-up with contrast imaging is required to confirm aneurysmal sac exclusion. The main objective of this study was to quantify and evaluate miRNA expression response to EVAR based on serum dosages at the 6-month follow-up. POPULATION AND METHOD: 47 patients with indication for EVAR were recruited and 10 patients without comorbidities. miRNA-181b and miRNA-21 were selected for this study and their serum dosages were measured at two time points: preoperatively and after 6 months of follow-up, and only once in the control group. Demographic profiles, clinical follow-ups, and imaging examinations with angiotomography performed preoperatively and after 6 months were collected. RESULTS: Overexpression of miRNA-181b and miRNA-21 was observed in the whole blood of patients with AAA. EVAR of patients with AAA resulted in decreased expression of the studied miRNAs, indicating that exclusion of the aneurysmal sac alters the expression of these markers. In addition, the expressions of miRNAs did not correlate with endoleaks or the diameter of the aneurysm or with the different types of devices used for the EVAR. CONCLUSIONS: The overexpression of miRNA-181b, miRNA-21 with its reduction after EVAR, may suggest the use of these molecules as potential biomarkers in the follow-up of these patients. However, miRNAs were not able to identify possible endoleaks or discriminate them into subtypes.Clinical ImpactThe clinical application of the use of biomarkers in other areas such as oncology is already well established. In endovascular surgery it is still incipient although with great potential in daily practice, in order to anticipate or schedule possible interventions in patients with endoleak. In addition, understand the mechanisms of action of miRNAs in Atherosclerotic diseases and aortic syndromes could provide a better understanding of the pathophysiology as well as pharmacological development for AAA prevention as well as remodeling of the aneurysm sac after EVAR.
引用
- Leite TFO, da Silva ER, Evelyn K, et al. Expression of Plasma Levels of miRNA-181b and miRNA-21 in Patients With Abdominal Aortic Aneurysms and Their Effect on Clinical Outcome After Endovascular Treatment. J Endovasc Ther. 2025. PMID: 39878154. doi:10.1177/15266028251314352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。